+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease



Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease



Journal of Clinical Investigation 100(1): 127-135



The recently described anti-A2/RA33 autoantibodies occur in 20-40% of patients with RA, SLE, and mixed connective tissue disease (MCTD). They are directed to the A2 protein of the heterogeneous nuclear ribonucleoprotein complex (hnRNP-A2), an abundant nuclear protein associated with the spliceosome. The NH-2-terminal half of the antigen contains two conserved RNA binding domains whereas its COOH-terminal part is extremely glycine-rich. The aim of this study was to characterize the autoepitopes of hnRNP-A2 and to investigate the effects of anti-A2/RA33 autoantibodies on possible functions of the antigen. Using bacterially expressed fragments, two major discontinuous epitopes were identified. One containing the complete -second RNA binding domain was recognized by the majority of patients with RA and SLE but not by patients with MCTD. The second epitope contained sequences of both RNA binding domains and was preferentially targeted by patients with MCTD. When the RNA binding properties of the antigen were investigated, oligoribonucleotide containing the sequence motif r(UUAG) were found to bind to a site closely adjacent or overlapping with the epitope targeted by autoantibodies from patients with RA and SLE. Moreover, anti-A2/RA33 autoantibodies from patients with RA or SLE, but not from patients with MCTD, inhibited binding of RNA. Thus, anti-A2/RA33 autoantibodies recognize conformation-dependent epitopes located in a functionally important region of the antigen. Furthermore, the specific recognition of an epitope by MCTD patients may be used as another argument in favor of considering MCTD a distinct connective tissue disease.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045268156

Download citation: RISBibTeXText

PMID: 9202064


Related references

Aberrant Expression of the Autoantigen Heterogeneous Nuclear Ribonucleoprotein-A2 (Ra33) and Spontaneous Formation of Rheumatoid Arthritis-Associated Anti-Ra33 Autoantibodies in Tnf- Transgenic Mice. The Journal of Immunology 175(12): 8327-8336, 2005

Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-alpha transgenic mice. Journal of Immunology 175(12): 8327-8336, 2005

Epitope mapping of the U1 small nuclear ribonucleoprotein particle in patients with systemic lupus erythematosus and mixed connective tissue disease. Lupus 20(3): 274-289, 2011

Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease. Lupus 22(13): 1371-1381, 2014

Differential epitope recognition by ANTI-hnRNP-A2/RA33 autoantibodies in polyarticular juvenile rheumatoid arthritis and RA. Arthritis & Rheumatism 41(9 SUPPL ): S343, Sept, 1998

Autoantibodies to the nuclear antigen hnRNP-A2 (RA33) in animal models of rheumatoid arthritis and systemic lupus erythematosus. Immunology Letters 56(Part-P2): 369-0, 1997

Serial estimation of anti-RNP antibody titers in systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis. Journal of Clinical and Laboratory Immunology 13(1): 15-19, 1984

HLA-DR in patients with systemic lupus erythematosus with anti-ribonucleoprotein antibodies and in mixed connective tissue disease. Revista do Hospital das Clinicas 40(6): 249-253, 1985

Quantitation of anti ribonucleoprotein and anti sm antibodies in mixed connective tissue disease and systemic lupus erythematosus patients by immunoblotting. Clinical & Experimental Immunology 59(2): 457-466, 1985

Herpes zoster in connective tissue diseases: II. Rheumatoid arthritis and mixed connective tissue disease in comparison with systemic lupus erythematosus. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 65(11): 1389-1393, 1991

Clinical significance of IgG subclasses of Anti-Sm and U1 ribonucleoprotein antibodies in patients with systemic lupus erythematosus and mixed connective tissue disease. Journal of Clinical Immunology 11(6): 317-325, 1991

Leukocytoclastic vasculitis in the facial lesions in cases of mixed connective tissue disease and systemic lupus erythematosus with a high titer of anti ribonucleoprotein antibodies. Nishinihon Journal of Dermatology 47(2): 236-241, 1985

Patterns of antihistone antibody specificity in systemic rheumatic disease 1. systemic lupus erythematosus mixed connective tissue disease primary sicca syndrome and rheumatoid arthritis with vasculitis. Arthritis and Rheumatism 28(3): 285-293, 1985

Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis and Rheumatism 38(6): 777-785, 1995

T-lymphocyte values in peripheral blood in systemic lupus erythematosus and similar nosological entities (progressive systemic sclerosis, rheumatoid arthritis, and mixed connective tissue disease). Casopis Lekaru Ceskych 121(12): 370-374, 1982